Immune-Mediated Side Effects of Programmed Death Ligand Inhibitors19–22
| Drug | Immune-Mediated Side Effect Colitis | Pneumonitis | Hepatitis | Adrenal Insufficiency | Thyroid Dysfunction | Hypophysitis | Diabetes Mellitus 1 | Renal Dysfunction |
|---|---|---|---|---|---|---|---|---|
| Pembrolizumab | 1.7% | 3.4% | 0.7% | 0.0% | 12.5% | 0.6% | 0.2% | 0.3% |
| Atezolizumab | 19.7% | 2.6% | 2.3% | 0.4% | 4.9% | 0.2% | 0.2% | 0.0% |
| Nivolumab | 2.9% | 3.1% | 1.8% | 1.0% | 11.7% | 0.6% | 0.9% | 1.2% |
| Avelumab | 1.5% | 1.2% | 0.9% | 0.5% | 6.0% | 0.0% | 0.1% | 0.1% |